Business

Par Pharmaceutical's board of directors has voted unanimously in favor of acquisition by private investment firm TPG for $1.9 billion, with Par shareholders getting $50 cash per share of Par common stock. Par and its subsidiary Strativa market several OINDPs, including Nascobal cyanocobalamin nasal spray and Miacalcin calcitonin nasal spray. Par Chairman and CEO … [Read more...] about Private investment firm to acquire Par Pharmaceutical

Gerresheimer is adding 3,500 square meters to its medical plastics facility in Horsovsky Tyn, Czech Republic, at a cost of about €18 million, adding to a previously announced expansion at the site. According to the company, it will hire approximately 200 more personnel over the next two years to handle increased production of inhalers and other devices at the site. … [Read more...] about Gerresheimer adds inhaler manufacturing capability in the Czech Republic

Hi-Tech Pharmacal has reported a 10% increase in net sales of generic products for the quarter ended April 30, 2012 compared to the same quarter in 2011, an increase due primarily to a sales increase for fluticasone proprionate nasal spray. According to the company, sales of fluticasone propionate nasal spray were up from $26.9 million in the same period last year to … [Read more...] about Hi-Tech Pharmacal attributes sales increase to nasal sprays

Renaissance Acquisition Holdings has acquired Texas-based CDMO DPT Laboratories, which offers MDI and nasal spray testing and manufacturing. DPT has facilities in San Antonio, TX and Lakewood, NJ. According to the company, the management team and business will continue as before. DPT President and COO Paul Johnson commented, “Renaissance and its management team … [Read more...] about DPT Labs acquired by Renaissance

Prosonix and Imperial College London have signed an agreement to collaborate on development of inhaled therapies based on multi-component particles (MCPs) manufactured using Prosonix's proprietary particle engineering technology. The company will coordinate with Dr. Omar Usmani of the college's National Heart and Lung Institute (NHLI) to perform in vivo and in vitro … [Read more...] about Prosonix and Imperial College London to collaborate on inhaled drugs

According to Insmed Incorporated, the company has entered into a loan agreement with Hercules Technology Growth Capital that will allow it to access up to $20 million for continued development of Arikace inhaled liposomal amikacin. Hercules received a warrant to purchase 329,932 shares of Insmed common stock at $2.94 per share as part of the agreement. Insmed … [Read more...] about Insmed gets $20 million loan

GlaxoSmithKline has acquired rights to several inhaled drug candidates manufactured using Liquidia Technologies' PRINT (Particle Replication In Non-Wetting Templates) platform. The PRINT nanofabrication technology produces particles with narrow size distribution and any desired shape. According to Liquidia, the total value of the deal, including an upfront payment, … [Read more...] about GSK gets rights to certain Liquidia Technologies inhalation candidates

Particle design and dry powder inhalation specialist Hovione has announced that sales for the fiscal year that ended in March, 2012 increased to $180 million,a 24% increase over the previous year. In addition to inhalation formulation development and manufacturing, the company also licenses its proprietary dry powder inhalers. Hovione CFO Miguel Calado commented, … [Read more...] about Hovione sales up 24%

MicroDose Therapeutx and Moerae Matrix have agreed to collaborate on development of a dry powder inhaler, using MicroDose DPI technology to deliver Moerae’s MMI-0100 MK2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). There are no treatments for IPF currently approved in the US. According to the companies, "MMI-0100 is a selective inhibitor of … [Read more...] about MicroDose Therapeutx and Moerae Matrix to collaborate on inhaled MK2 inhibitor

According to Bloomberg News, Merck plans to appeal a ruling by Judge Peter Sheridan of the US District Court for the District of New Jersey that Merck failed to prove its allegation that Apotex infringed on its Nasonex patent. At the same time, the judge upheld the validity of the patent, which Apotex had challenged. Apotex filed an ANDA for mometasone nasal … [Read more...] about Judge rules for Apotex in Merck’s Nasonex patent infringement suit